FDA extends review of application for OCREVUS™ (ocrelizumab)
Roche announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics Licence Application (BLA) of OCREVUS™ (ocrelizumab) to 28th March 2017.
Sorry people...
http://www.roche.com/media/store/rel...2016-12-20.htm
Roche announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Biologics Licence Application (BLA) of OCREVUS™ (ocrelizumab) to 28th March 2017.
Sorry people...
http://www.roche.com/media/store/rel...2016-12-20.htm